GIGYF1

Across TCGA pan-cancer cohorts, GIGYF1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GIGYF1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GIGYF1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GIGYF1 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where GIGYF1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GIGYF1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.140	<.001	8	view →
PDAC	All	All	−0.293	<.001	7	view →
LUAD	Male	All	−0.091	.003	4	view →
OV	All	All	−0.382	.014	2	view →
COAD	All	All	−0.357	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

GIGYF1–CCRCC

Open the CCRCC breakdown →